Hodgkin Disease
Consolidation chemotherapy for relapsed/refractory Hodgkin disease feasible
Published in Cancer Weekly, January 18th, 2005
According to published research from the United States, "Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT) for Hodgkin's disease (HD).
"The administration of non-crossresistant therapies during the post-transplant period may delay or prevent relapse. We prospectively studied the role of consolidation chemotherapy (CC) after auto-PBSCT in 37 patients with relapsed or refractory HD."
"Patients received high-dose gemcitabine-BCNU-melphalan and auto-PBSCT followed by involved-field radiation and up to four cycles...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-01-18)
More Articles from Cancer Weekly
- Breast Cancer
Cancer detected by screening mammography associated with less toxic therapy - Cancer Genetics
BRCA1 mutation prevalence in ovarian tumors is low in Norway - Cancer Therapy
Riddelliine mutagenicity different in liver endothelial and parenchymal cells - Colon Cancer
Chemotherapy useful for liver metastases from colorectal cancer - Hepatocellular Carcinoma
Dendritic cells elicit T-cell-mediated immune responses to HCA587 protein - Acute Myeloid Leukemia
Genes with prognostic value identified in childhood AML with FLT3 mutations - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
